Deprivation Study. The Freiburg Study

Similar documents
Supplementary Table 1. Patient demographics and baseline characteristics (treated patients).

Integrated Health/Person Centered Health Home Austin Travis County Integral Care

Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Your health is a crucial aspect of your life. That s why the Yakima Heart Center offers this booklet; to help you identify the numbers that affect

What s New in Bariatric Surgery?

Your Name & Phone Number Here! Longevity Index

Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms

Test5, Here is Your My5 to Health Profile with Metabolic Syndrome Insight

High intensity exercise improves cardiac structure and function and reduces liver fat in adults with Type 2 diabetes

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

The Rice Diet of Central Florida

Insulin resistance influences 24h heart rate and blood pressure variabilities and cardiovascular autonomic modulation in normotensive healthy adults

Blood Pressure 1 of 22 Boardworks Ltd 2011

RISK FACTORS OR COMPLICATIONS AND RECOMMENDED TREATMENT GOALS AND FREQUENCY OF EVALUATION FOR ADULTS WITH DIABETES

Risk Factors for Heart Disease

Session 21: Heart Health

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution

Patient Education. intermountainhealthcare.org/diabetes. BG Tracker. for people with diabetes MONITORING BLOOD GLUCOSE

Type 2 diabetes in Tuvalu: A drug use and chronic disease management evaluation. Prepared for the Ministry of Health, Tuvalu.

Cleveland Clinic Heart Health Survey

Clinical Trial Synopsis TL-OPI-525, NCT#

Statistical Analysis Plan FINAL. DexComG4 (DexCom Corporation) CGMMDI GOLD-Study

Screening Results. Juniata College. Juniata College. Screening Results. October 11, October 12, 2016

AUTONOMIC FUNCTION IS A HIGH PRIORITY

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015

Report Operation Heart to Heart

Care Facilitation Quality Improvement Report

NRAO-NM HEALTH FAIR 2017 ALLEN BASSLER, MD

Session 2016: Sections: Class Location: Days / Time: Instructor:

Conflict of interest regarding this presentation:

RICHMOND PARK SCHOOL LIFESTYLE SCREENING REPORT Carmarthenshire County Council

Supplemental Table S2: Subgroup analysis for IL-6 with BMI in 3 groups

Swallowing Your Pills (2 slides)

2013 Hypertension Measure Group Patient Visit Form

Results/ conclusion. Reference Duration Number subjects. Study description. Limitations of the data. Randomized controlled trial (RCT)

Fructose in diabetes: Friend or Foe. Kim Chong Hwa MD,PhD Sejong general hospital, Division of Endocrinology & Metabolism

Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography

National Collaborative Wave 2 (Wave 9): National Diabetes Prevention and Management Wave, Month 9 Diabetes Management: Diabetes Register

Understanding Cholesterol and Triglycerides

Clinical Care Performance. Financial Year 2012 to 2018

Supplementary Online Content

Metabolic Syndrome: A Preventable & Treatable Cluster of Conditions

A pilot Study of 25-Hydroxy Vitamin D in Egyptian Diabetic Patients with Diabetic Retinopathy

Metabolic Syndrome.

Clinical Study Synopsis

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up

DIABETES. A growing problem

University College Hospital. Diabetes annual review

David Wright, MD Speaking of Women s Health Shawnee Mission Medical Center October 4, 2013

DMEP Study Section 1 1

Nature Medicine: doi: /nm.3891

SITA 100 mg (n = 378)

Preparing for the road ahead. LEARN MORE ABOUT these 5 risks

Lipoprotein Particle Profile

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?

Cardiovascular System and Health. Chapter 15

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects

NOT-FED Study New Obesity Treatment- Fasting, Exercise, Diet

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk

Know Your Numbers. Your guide to maintaining good health. Helpful information from Providence Medical Center and Saint John Hospital

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Association between arterial stiffness and cardiovascular risk factors in a pediatric population

Scottish Diabetes Survey 2012

CARDIOVASCULAR HEALTH

SCIENTIFIC STUDY REPORT

Downloaded from journal.qums.ac.ir at 10: on Sunday February 17th 2019

CARE PATHWAYS. Allyson Ashley

Supplementary Online Content

Proven and Proposed Cardiovascular Benefits of Soyfoods

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu

Metabolic Syndrome Is A Key Determinant Of Coronary Microvascular Function In Patients With Stable Coronary Disease Undergoing PCI

Effects of whole grain intake on weight changes, diabetes, and cardiovascular Disease

The Journey towards Total Wellbeing A Health System s Innovative Approach

To reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees.

Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound

The role of physical activity in the prevention and management of hypertension and obesity

Diabetes. Ref HSCW 024

Pro and Cons of Intermittent Fasting

What is Diabetes Mellitus?

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.

Supplementary Information for: Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative.

Weight as a Measure of Health vs. Health at Every Size

Diabetes Self-Management Education Record

Gender: M Chart No: Fasting: Yes. Boston Heart HDL Map TM Test 1 ApoA-I (mg/dl) levels in HDL particles. α Range > <14 mg/dl. α-2 50.

Health First. New Health Bucks Program MANATEE YOURCHOICE HEALTH PLAN

Case study for CME Diabetes up-to-date management

Director, Employee Health & Productivity. Coordinator, Employee Health & Productivity

Diabetes and Weight Management: Tools to Affect Patient Outcomes

SUPPLEMENTARY DATA. Supplementary Figure 1. PubMed

Supplementary Appendix

Traditional Asian Soyfoods. Proven and Proposed Cardiovascular Benefits of Soyfoods. Reduction (%) in CHD Mortality in Eastern Finland ( )

Supplementary Appendix

Cardiovascular Disease Risk Factors:

Widespread concern about the role of SFA in heart disease: Is it justified?

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

LEPTIN AS A NOVEL PREDICTOR OF DEPRESSION IN PATIENTS WITH THE METABOLIC SYNDROME

Diabetes Passport. East Coast Area Diabetes Integrated Care

Supplementary Figure 1

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Transcription:

The Freiburg Study Deprivation Study Free Radicals Inflammation (hs-crp) Blood Pressure (Systolic, Diastolic) Blood Lipids (Cholesterol, Triglycerides) Energy Utilization (Heart Rate) Sugar Metabolism (Blood Glucose, HOMA, HbA1c)

Adding years to your life and life to your years requires consistent usage. The follow-up Deprivation Study. Twelve weeks after the completion of the Freiburg Study, Freiburg researchers conducted a deprivation follow-up. This study revealed some of the most insightful pieces of data yet: almost all of the benefits participants gained from using the Pack had all but vanished! In almost every instance, key health markers like free radicals, blood pressure, inflammation, cholesterol, and heart rate had already returned to less-healthy, pre-study levels. Freiburg Study methodology. Twelve weeks after the end of the original Freiburg Study, a total of 31 of the original 48 Freiburg subjects returned to participate in this deprivation portion of the study. In order to qualify for the follow-up study, subjects had to have not made any changes to their diet or exercise after the completion of the original study. The only change was to have stopped taking the Pack. Following protocols developed for the original Freiburg Study, subjects were tested for all 25 health markers to determine if any change had taken place. 31 DEPRIVATION SUBJECTS Two-thirds of the original Freiburg Study participants returned for the deprivation follow-up.

μm/min 2.20 Understanding the graphs. 2.00 1.80 1.60 To demonstrate not only the profound effects of the Pack, but also the need for ongoing, we have created these graphs from the data obtained from the initial Freiburg Study as well as the Deprivation Study. To present the most accurate results, we have isolated and are showing only the data from the 31 subjects who participated in both the original Freiburg Study and the Deprivation Study. 1.40 1.20 1.00 The first bar shows the subjects health marker before taking the Pack. The middle bar shows the effect on the health marker after taking the Pack continuously for. 16.2% The data in the blue circle highlights the average improvements subjects saw after taking the Peak Performance Pack. The final bar shows the health marker after the subjects stopped taking. 22.1% The data in the red circle indicates the average loss of benefit subjects experienced the Pack. Calculated as a percent change of the before number. Calculated as a percent change of the number.

Free Radicals after subjects began taking the Pack, their average free radical levels dropped 16.2%. After they stopped taking, the levels increased 22.1%. Inflammation: hs-crp A protein in the blood called hs-crp increases when inflammation levels rise. These values are a good indicator of the amount of inflammation in the body. Twelve weeks after subjects began taking the Pack, their hs-crp values dropped 18.8%. After they stopped taking, it increased 46.2%. μm/min 2.20 2.40 2.00 2.20 1.80 1.60 1.40 1.20 2.00 1.80 1.60 1.40 1.20 1.00 1.00 16.2% 22.1% 18.8% 46.2%

Blood Pressure: Systolic While on the Pack, subjects saw a 5.2% improvement in their average systolic blood pressure. After they stopped taking, their blood pressure increased by 3.3%. Blood Pressure: Diastolic While on the Pack, subjects average diastolic blood pressure dropped 4.7%. After they stopped taking, those levels increased 1.7%. mmhg 124 mmhg 84 122 82 120 80 118 78 116 76 114 74 112 72 110 70 5.2% 3.3% 4.7% 1.7%

Blood Lipids: Total Cholesterol Performance Pack, their total cholesterol levels dropped 6.8%. After they stopped taking, their cholesterol levels rose 4.6%. Blood Lipids: LDL Cholesterol Performance Pack, their average LDL (or bad cholesterol) dropped 8.2%. After they stopped taking, it increased 10.4%. 250 150 240 145 230 140 220 135 210 130 200 125 190 120 180 115 170 110 6.8% 4.6% 8.2% 10.4%

Blood Lipids: HDL Cholesterol Higher levels of HDL (good cholesterol) help reduce the risk of heart disease. Twelve weeks after subjects began taking the Pack, their average HDL increased 12.9%. After they stopped taking, it dropped 7.4%. Blood Lipids: Triglycerides Performance Pack, their average triglyceride levels dropped 14.0%. After they stopped taking, their triglyceride levels increased 18.6%. 90 85 80 75 70 65 60 55 50 45 40 160 140 120 100 80 60 40 12.9% 7.4% 14.0% 18.6%

Energy Utilization: Heart Rate Performance Pack, their average heart rate fell by 5 beats per minute during excercise. After they stopped taking, it increased by 6 beats per minute. Blood Glucose Spike Performance Pack, their average blood sugar spikes dropped 47.3%. After they stopped taking, blood sugar spikes rose 29.3%. bpm 135.0 130.0 125.0 120.0 60 50 40 30 20 10 115.0 0 5 bpm 6 bpm 47.3% 29.3%

Sugar Metabolism: HOMA Performance Pack, an 11.1% decrease in the HOMA index a measure of insulin sensitivity was observed. After they stopped taking, it increased 16.7%. Sugar Metabolism: HbA1c Performance Pack, their average HbA1c which shows an overall picture of average blood sugar levels over a period of 90 days decreased by 3.6%. After they stopped taking, it increased 1.5%. HOMA 3.0 2.9 2.8 2.7 2.6 2.5 2.4 2.3 2.2 2.1 2.0 mmol/mol 40.0 39.0 38.0 37.0 36.0 35.0 34.0 33.0 32.0 31.0 30.0 11.1% 16.7% 3.6% 1.5%